AUTHORS
Xuan Zhou, PhD, Honghua He2, Zhenfang LIU, MD3, Yongzhong Su4, Lie Lin5, Qiang WANG, MD6, guanlian yang7, Shaoze Lin8, Jiayi Li9, Bingyu Lin10, yan zhang11, Yangpeng Chen12, Qifa Liu, MD13, Xiaoli Liu, MD14, Na Xu15
AFFILIATIONS
1 Department of Hematology, Nanfang Hospital, Southern Medical University, guangzhou, China
2 Affiliated Hospital of Guangdong Medical University, zhanjiang, China
3 The First Affiliated Hospital of Guangxi Medical University, nanning, China
4 Department of Hematology, the first affiliated hospital of shantou university medical college, shantou, China
5 Department of Hematology, Hainan General Hospital, haikou, China
6 Department of Hematology, Nanfang Hospital, Southern Medical University, guangzhou, China
7 Affiliated Hospital of Guangdong Medical University, zhanjiang, China
8 Department of Hematology, the first affiliated hospital of shantou university medical college, shantou, China
9 Department of Hematology, Nanfang Hospital, Southern Medical University, guangzhou, China
10 Department of Hematology, Nanfang Hospital, Southern Medical University, guangzhou, China
11 Department of Hematology, Nanfang Hospital, Southern Medical University, guangzhou, China
12 Department of Hematology, Nanfang Hospital, guangzhou, China
13 Department of Hematology, Nanfang Hospital, Southern Medical University, guangzhou, China
14 Department of Hematology, Nanfang Hospital, Southern Medical University, guangzhou, China
15 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
ABSTRACT
Background:
Primary and post-polycythemia vera/essential thrombocythemia myelofibrosis (MF) are myeloproliferative neoplasms (MPN) characterized by splenomegaly, constitutional symptoms, hematological abnormalities, and risks of vascular complications and blast transformation. Ruxolitinib alleviates MF-related splenomegaly and symptoms but offers limited hematological improvement in cytopenic patients, and the durability of its splenic response remains suboptimal. Gecacitinib, a JAK/ACVR1 inhibitor, is approved for treating MF. However, real-world evidence regarding its use in both ruxolitinib-naïve and ruxolitinib-pretreated patients remains scarce. This retrospective real-world study evaluated the clinical performance of gecacitinib in MF patients.
Aims:
To evaluate the efficacy and safety of gecacitinib in ruxolitinib-naïve and ruxolitinib-pretreated patients with MF in a real-world setting.
Methods:
This retrospective, multicenter real-world analysis enrolled 112 patients with MF who received gecacitinib across 5 centers in China. Oral dosages were individually adjusted based on baseline hematological parameters.Endpoints included anemia responses, splenic respons, symptom responses, safety, and survival.
Results:
From June 2025 to July 2026, 31 ruxolitinib-naïve and 81 ruxolitinib-pretreated patients had received gecacitinib and were included in this analysis.
The ruxolitinib-naïve cohort comprised patients aged 36 to 81 years (median 62 years; 18 males, 13 females). 77.4% had primary myelofibrosis (PMF) and JAK2 mutation was detected in 61.3%. At baseline, 64.5% had severe anemia (hemoglobin [Hb] < 80 g/L). In the overall cohort, the mean baseline Hb was 80.2 g/L, with sustained increases observed over time (mean rise of 12 g/L at Week 6 and 18 g/L at Week 24). Patients with severe anemia (mean baseline Hb 66.0 g/L) showed greater improvements, with median Hb increases of 19 g/L at Week 6 and 26 g/L at Week 24.Furthermore, among 25 (80.6%) patients with baseline Hb < 100 g/L, 52.0% achieved Hb increase ≥20 g/L and 68.0% achieved ≥10 g/L increase within 12 weeks. Among 13 patients who completed 24 weeks of treatment and had baseline splenomegaly, 53.8% showed splenic response and 38.5% (5/13) achieved ≥20% spleen length reduction. With a median follow-up of 8.02 months (range, 1.71–12.62), no disease progression or death was observed (6-month progression-free survival (PFS) and overall survival (OS) rates: 100%). Only 2 patients (6.5%) discontinued treatment due to intolerance.
The ruxolitinib-pretreated cohort comprised patients aged 30 to 80 years (median 63 years; 41 males, 40 females). 63.0% had PMF and JAK2 mutation was detected in 56.8%. At baseline, 43.2% had severe anemia (Hb < 80 g/L). The median prior ruxolitinib exposure duration was 13.0 months (range, 0.5–93.7). In the overall cohort, the mean baseline Hb was 83.6 g/L, with sustained increases observed over time (mean rise of 8 g/L at Week 6 and 13 g/L at Week 24). Patients with severe anemia (mean baseline Hb 60.9 g/L) demonstrated greater improvements, with median Hb increases of 10 g/L at Week 6 and 25 g/L at Week 24. Furthermore, among 65 (80.2%) patients with baseline Hb < 100 g/L, 38.5% achieved a Hb increase ≥20 g/L and 64.6% achieved ≥10 g/L increase within 12 weeks. Among 32 patients who completed 24 weeks of treatment and had baseline splenomegaly, 62.5% showed splenic response and 25.0% (8/32) achieved ≥20% spleen length reduction. With a median follow-up of 8.51 months (range, 1.58–12.68), the 6-month PFS rate was 95.2% and the 6-month OS rate was 100%. Only 3 patients (3.7%) discontinued treatment due to intolerance.
Conclusions:
This retrospective real-world study demonstrates that gecacitinib has promising efficacy and a favorable safety profile in both JAK inhibitor-naïve and ruxolitinib-pretreated patients with MF, particularly in those with anemia. Updated analyses, including response durability and long-term follow-up, will be presented.
DISCLOSURES
Xuan Zhou, PhD: No relevant conflicts of interest to declare.